Skip to main content
. 2017 Nov 16;9(7):7739–7748. doi: 10.18632/oncotarget.22471

Figure 3.

Figure 3

(A) Meta-analysis for wild type overall survival of panitumumab, bevacizumab and cetuximab antibody therapies alone or in combination with FOLFOX-4 (for panitumumab and cetuximab). (B) Meta-analysis for mutant type overall survival of panitumumab, bevacizumab and cetuximab antibody therapies alone or in combination with FOLFOX-4 (for panitumumab and cetuximab).